Our global equity fund “ACTIS Aktien Global Fonds”, for quite a while now, has been paying attention to companies that have a strong position in the fight against viruses or bacteria.
In that arena, one of those companies that investors can find in the portfolio is the US Group “Gilead Science Inc”, a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
The company researches and commercializes therapies, such as for HIV, hepatitis B + C and influenza and was involved, among other projects, in the development of Roche's world-leading influenza medicine "Tamiflu". Under Gilead Science we also find Remdesivir, it was its drug candidate to fight against Ebola, it also showed to be a candidate to work against SARS and MERS. Remdesivir appears to be an effective way to treat COVID-19 symptoms, the drug is in two Phase3 clinical studies for its evaluation.
